IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT03665129

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03665129. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.

Study identification

NCT ID: NCT03665129
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Innate Pharma; Industry
Enrollment: 73 participants

Conditions and interventions

Conditions

Advanced Solid Tumors

Interventions

IPH5401 and Durvalumab Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 7, 2018 (Actual)
Primary completion: Feb 24, 2021 (Actual)
Completion: Feb 24, 2021 (Actual)
Last update posted: Jan 27, 2022

2018 – 2021

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
James Graham Brown Cancer Center	Louisville	Kentucky	40202	—
Park Nicollet Frauenshuh Cancer Center	Saint Louis Park	Minnesota	55426	—
ICAHN School of Medicine at Mount Sinai	New York	New York	10029-6574	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
NEXT Oncology	San Antonio	Texas	78006	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03665129, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 27, 2022 · Synced Nov 14, 2026